Intuitive Surgical stock holds near record levels on strong margins
Published on 07/24/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical (US46120E6023) has a case built on numbers, not noise: the stock closed at $144.24 on 23 July 2026, while first-quarter 2026 revenue rose 19% to $2.25 billion and non-GAAP gross margin reached 68.6%. The company also said da Vinci procedures increased 17% year over year in Q1 2026, giving the shares a current operational anchor.
Q1 2026 growth stays visible
For Intuitive Surgical stock, the first-quarter 2026 report still matters because it combines higher sales, broader procedure volume, and resilient profitability. Revenue increased from about $1.89 billion a year earlier to $2.25 billion, and non-GAAP net income came in at $768 million, up from $661 million in Q1 2025.
The comparison is the key point: $2.25 billion is 19% above the prior-year quarter, while $768 million in non-GAAP net income was 16% higher than the year-ago level. That kind of spread suggests the company is not only selling more systems and services, but also converting that growth into earnings.
Margins still do the work
Intuitive Surgical said non-GAAP gross margin was 68.6% in Q1 2026, up from 68.1% in Q1 2025, while non-GAAP operating margin was 39.0%, compared with 37.5% a year earlier. The figures matter because they show that revenue growth has not come at the expense of profitability.
The company also reported 311 da Vinci procedures per system in Q1 2026, up from 299 in Q1 2025. That 4% increase is smaller than the headline revenue gain, but it points to stronger utilization across the installed base, which tends to support recurring instruments and accessories revenue.
Market value near the top
At $144.24 on 23 July 2026, the shares were trading close to the upper end of their recent range, with a 52-week band of roughly $425.00 to $511.96 as reported in market data. The price level suggests investors are still assigning a premium to the company’s growth profile and surgical robotics moat.
The latest quarterly numbers help explain that valuation. Revenue growth of 19%, non-GAAP net income growth of 16%, and a 68.6% gross margin create a clean earnings backdrop at a time when many healthcare hardware names are dealing with slower growth or lower utilization.
da Vinci stays central
The main product line remains the da Vinci robotic surgery platform, which sits at the center of Intuitive Surgical’s installed-base economics. In Q1 2026, the company said procedure growth across that platform remained broad-based, and that is the metric investors usually watch more closely than headline system shipments.
For the business, the product story is simple: more procedures generally mean more recurring revenue from instruments, accessories, and service. That is why the 17% procedure increase in Q1 2026 matters even more than a one-quarter shipment swing.
Shares at $144.24
Intuitive Surgical stock finished at $144.24 on 23 July 2026, measured in USD on the Nasdaq listing. The same price sits alongside a Q1 2026 report that showed $2.25 billion in revenue, $768 million in non-GAAP net income, and 68.6% non-GAAP gross margin, which keeps the equity tied to a still-strong operating base.
Intuitive Surgical stock facts
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: NASDAQ: ISRG
- Trading venue: Nasdaq
- Price (as of 23 July 2026, 16:00 ET): $144.24 USD
- Sector / Industry: Health Care / Health Care Equipment
- Index membership: Nasdaq 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
